LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Pirola, Marta"
  2. AU="Justet, Aurélien"
  3. AU="Fujii, Ayako"
  4. AU=Reinhardt Dietrich
  5. AU="Lee, Sang-Gi"
  6. AU="Fernandez-Sobaberas, Jaime"
  7. AU="Nassani, Abdelmohsen A"
  8. AU=Benn Carol-Ann
  9. AU="Yongfeng Fan"
  10. AU="Merghani, M."
  11. AU="Shankar, Archana"
  12. AU="Lau, Wilma"
  13. AU="Milosević-Stevanović, Jelena" AU="Milosević-Stevanović, Jelena"
  14. AU="Levens, Cassandra"
  15. AU=Gerdes Hans-Hermann
  16. AU="Johnson, Abigail N"
  17. AU="Zheng, Yuanyuan"
  18. AU="Xia, Fan"
  19. AU="Wilson, Louis G"
  20. AU="Aubertin, Perrine"
  21. AU=Remmel Ariana
  22. AU="Tabbo, Agnese"
  23. AU="Chen, Linyi"
  24. AU="Milovanovic, Marija"
  25. AU="Vaught, Emma K"
  26. AU="Chapelle, Caroline"
  27. AU="Schmelzeisen, R"
  28. AU=Sillanaukee P AU=Sillanaukee P
  29. AU="Meyler, Shanique"

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: Immunotherapy in urothelial cancer: current status and future directions.

    Piombino, Claudia / Tonni, Elena / Oltrecolli, Marco / Pirola, Marta / Pipitone, Stefania / Baldessari, Cinzia / Dominici, Massimo / Sabbatini, Roberto / Vitale, Maria Giuseppa

    Expert review of anticancer therapy

    2023  Band 23, Heft 11, Seite(n) 1141–1155

    Abstract: Introduction: Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting from second-line treatment has led to an improvement in overall survival in locally advanced and metastatic urothelial cancer (UC). Clinical trials are ... ...

    Abstract Introduction: Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting from second-line treatment has led to an improvement in overall survival in locally advanced and metastatic urothelial cancer (UC). Clinical trials are underway testing the role of ICIs since the first stages of the disease, alone or in combination with standard therapies.
    Areas covered: This review summarizes the current updated evidence regarding the role of ICIs in the different stages of UC, the ongoing clinical trials exploring the potential benefit of immunotherapy alone or in combination with standard-of-care therapies, as well as the promising association of ICIs with antibody-drug conjugates (ADCs).
    Expert opinion: In the first-line setting, ICIs alone in platinum-unfit patients have shown unconvincing results; the ongoing EV-302 trial will probably suggest enfortumab vedotin plus pembrolizumab as a new effective option. The optimal duration of maintenance immunotherapy is still to be determined, finding a balance with the risk-benefit profile. The clinical benefit of ICIs as second-line treatment is limited to a subset of patients that cannot be definitively established yet. In the next 5 years, a lot of new ADCs will likely emerge for the treatment of UC.
    Mesh-Begriff(e) Humans ; Urinary Bladder Neoplasms/pathology ; Carcinoma, Transitional Cell/pathology ; Immunotherapy/methods ; Immunoconjugates
    Chemische Substanzen Immunoconjugates
    Sprache Englisch
    Erscheinungsdatum 2023-10-27
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2023.2265572
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5907: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.

    Piombino, Claudia / Pipitone, Stefania / Tonni, Elena / Mastrodomenico, Luciana / Oltrecolli, Marco / Tchawa, Cyrielle / Matranga, Rossana / Roccabruna, Sara / D'Agostino, Elisa / Pirola, Marta / Bacchelli, Francesca / Baldessari, Cinzia / Baschieri, Maria Cristina / Dominici, Massimo / Sabbatini, Roberto / Vitale, Maria Giuseppa

    International journal of molecular sciences

    2024  Band 25, Heft 9

    Abstract: More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment ... ...

    Abstract More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment of metastatic prostate cancer with PARP inhibitors in this subset of patients, especially in the case of
    Mesh-Begriff(e) Humans ; Male ; Recombinational DNA Repair ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; BRCA2 Protein/genetics ; BRCA2 Protein/deficiency ; Neoplasm Metastasis ; BRCA1 Protein/genetics ; BRCA1 Protein/deficiency ; Phthalazines/therapeutic use ; Phthalazines/pharmacology ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Piperazines
    Chemische Substanzen Poly(ADP-ribose) Polymerase Inhibitors ; BRCA2 Protein ; BRCA1 Protein ; BRCA2 protein, human ; Phthalazines ; olaparib (WOH1JD9AR8) ; Receptors, Androgen ; BRCA1 protein, human ; Piperazines
    Sprache Englisch
    Erscheinungsdatum 2024-04-24
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25094624
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.

    Baldessari, Cinzia / Pipitone, Stefania / Molinaro, Eleonora / Cerma, Krisida / Fanelli, Martina / Nasso, Cecilia / Oltrecolli, Marco / Pirola, Marta / D'Agostino, Elisa / Pugliese, Giuseppe / Cerri, Sara / Vitale, Maria Giuseppa / Madeo, Bruno / Dominici, Massimo / Sabbatini, Roberto

    Cancers

    2023  Band 15, Heft 5

    Abstract: Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. Bone ... ...

    Abstract Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. Bone metastases start with the tropism of cancer cells to the bone through different multi-step tumor-host interactions, as described by the "metastatic cascade" model. Understanding these mechanisms, although far from being fully elucidated, could offer several potential targets for prevention and therapy. Moreover, the prognosis of patients is markedly influenced by skeletal-related events. They can be correlated not only with bone metastases, but also with "bad" bone health. There is a close correlation between osteoporosis-a skeletal disorder with decreased bone mass and qualitative alterations-and prostate cancer, in particular when treated with androgen deprivation therapy, a milestone in its treatment. Systemic treatments for prostate cancer, especially with the newest options, have improved the survival and quality of life of patients with respect to skeletal-related events; however, all patients should be evaluated for "bone health" and osteoporotic risk, both in the presence and in the absence of bone metastases. Treatment with bone-targeted therapies should be evaluated even in the absence of bone metastases, as described in special guidelines and according to a multidisciplinary evaluation.
    Sprache Englisch
    Erscheinungsdatum 2023-02-28
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15051518
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Cerebellar metastasis of ovarian cancer: a case report.

    Cabitza, Eleonora / Pirola, Marta / Baldessari, Cinzia / Bernardelli, Giuditta / Zunarelli, Elena / Pipitone, Stefania / Vitale, Maria Giuseppa / Nasso, Cecilia / Molinaro, Eleonora / Oltrecolli, Marco / D'Agostino, Elisa / Mandato, Vincenzo Dario / Palicelli, Andrea / Dominici, Massimo / Sabbatini, Roberto

    Journal of medical case reports

    2023  Band 17, Heft 1, Seite(n) 553

    Abstract: Background: Ovarian cancer is metastatic at presentation in about 62% of cases, but brain metastases are rare, reported in 3.3-4% of patients. Brain metastasis seems to be more frequent in advanced stages at diagnosis and in patients with BRCA1/2 ... ...

    Abstract Background: Ovarian cancer is metastatic at presentation in about 62% of cases, but brain metastases are rare, reported in 3.3-4% of patients. Brain metastasis seems to be more frequent in advanced stages at diagnosis and in patients with BRCA1/2 mutation.
    Case presentation: We present a case of a 47-year-old Caucasian woman, BRCA wild type, with an ovarian cancer that started with single cerebellar metastasis.
    Conclusion: Brain metastases in ovarian cancer are rare and complex for diagnosis and management. This case focuses both on diagnosis and treatment, emphasizing the importance of a multimodal approach in a multidisciplinary team.
    Mesh-Begriff(e) Humans ; Female ; Middle Aged ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Ovarian Neoplasms/pathology ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/therapy ; Brain Neoplasms/genetics
    Chemische Substanzen BRCA1 protein, human ; BRCA1 Protein ; BRCA2 protein, human ; BRCA2 Protein
    Sprache Englisch
    Erscheinungsdatum 2023-12-19
    Erscheinungsland England
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 2269805-X
    ISSN 1752-1947 ; 1752-1947
    ISSN (online) 1752-1947
    ISSN 1752-1947
    DOI 10.1186/s13256-023-04211-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

    Piombino, Claudia / Oltrecolli, Marco / Tonni, Elena / Pirola, Marta / Matranga, Rossana / Baldessari, Cinza / Pipitone, Stefania / Dominici, Massimo / Sabbatini, Roberto / Vitale, Maria Giuseppa

    Cancers

    2023  Band 15, Heft 20

    Abstract: De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5-10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new ...

    Abstract De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5-10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. This review describes the current therapeutic opportunities for de novo mHSPC, focusing on potential molecular biomarkers identified in the main clinical trials that have modified the standard of care, the genomic features of de novo mHSPC, and the principal ongoing trials that are investigating new therapeutic approaches and the efficacy of a biomarker-guided treatment in this setting. The road toward personalized treatment for de novo mHSPC is still long, considering that the randomized clinical trials, which have furnished the basis of the current therapeutic options, stratified patients according to clinical criteria that did not necessarily reflect the biological rationale of the chosen therapy. The role of transcriptomic profiling of mHSPC as a predictive biomarker requires further validation, and it remains to be ascertained how the genomic variants detected in mHSPC, which are regarded as predictive in the castration-resistant disease, can be exploited in the mHSPC setting.
    Sprache Englisch
    Erscheinungsdatum 2023-10-11
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15204945
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel: Cultured Horse Articular Chondrocytes in 3D-Printed Chitosan Scaffold With Hyaluronic Acid and Platelet Lysate.

    De Angelis, Elena / Saleri, Roberta / Martelli, Paolo / Elviri, Lisa / Bianchera, Annalisa / Bergonzi, Carlo / Pirola, Marta / Romeo, Roberta / Andrani, Melania / Cavalli, Valeria / Conti, Virna / Bettini, Ruggero / Passeri, Benedetta / Ravanetti, Francesca / Borghetti, Paolo

    Frontiers in veterinary science

    2021  Band 8, Seite(n) 671776

    Abstract: Three-dimensional (3D) printing has gained popularity in tissue engineering and in the field of cartilage regeneration. This is due to its potential to generate scaffolds with spatial variation of cell distribution or mechanical properties, built with a ... ...

    Abstract Three-dimensional (3D) printing has gained popularity in tissue engineering and in the field of cartilage regeneration. This is due to its potential to generate scaffolds with spatial variation of cell distribution or mechanical properties, built with a variety of materials that can mimic complex tissue architecture. In the present study, horse articular chondrocytes were cultured for 2 and 4 weeks in 3D-printed chitosan (CH)-based scaffolds prepared with or without hyaluronic acid and in the presence of fetal bovine serum (FBS) or platelet lysate (PL). These 3D culture systems were analyzed in terms of their capability to maintain chondrocyte differentiation
    Sprache Englisch
    Erscheinungsdatum 2021-07-12
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2834243-4
    ISSN 2297-1769
    ISSN 2297-1769
    DOI 10.3389/fvets.2021.671776
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang